VANBIERVLIET, G., M. STRIJKER, M. ARVANITAKIS, A. AELVOET, U. ARNELO, T. BEYNA, O. BUSCH, P. H. DEPREZ, Lumír KUNOVSKÝ, A. LARGHI, G. MANES, A. MOSS, B. NAPOLEON, M. NAYAR, E. PEREZ-CUADRADO-ROBLES, S. SEEWALD, M. BARTHET and J. E. VAN HOOFT. Endoscopic management of ampullary tumors: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. STUTTGART: GEORG THIEME VERLAG KG, 2021, vol. 53, No 04, p. 429-448. ISSN 0013-726X. Available from: https://dx.doi.org/10.1055/a-1397-3198.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Endoscopic management of ampullary tumors: European Society of Gastrointestinal Endoscopy (ESGE) Guideline
Authors VANBIERVLIET, G. (guarantor), M. STRIJKER, M. ARVANITAKIS, A. AELVOET, U. ARNELO, T. BEYNA, O. BUSCH, P. H. DEPREZ, Lumír KUNOVSKÝ (203 Czech Republic, belonging to the institution), A. LARGHI, G. MANES, A. MOSS, B. NAPOLEON, M. NAYAR, E. PEREZ-CUADRADO-ROBLES, S. SEEWALD, M. BARTHET and J. E. VAN HOOFT.
Edition Endoscopy, STUTTGART, GEORG THIEME VERLAG KG, 2021, 0013-726X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30212 Surgery
Country of publisher Germany
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 9.776
RIV identification code RIV/00216224:14110/21:00121429
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1055/a-1397-3198
UT WoS 000629334400001
Keywords in English ampullary tumors; endoscopic management
Tags 14110213, 14110223, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 17/5/2022 09:00.
Abstract
Main Recommendations 1 ESGE recommends against diagnostic/therapeutic papillectomy when adenoma is not proven. Strong recommendation, low quality evidence. 2 ESGE recommends endoscopic ultrasound and abdominal magnetic resonance cholangiopancreatography (MRCP) for staging of ampullary tumors. Strong recommendation, low quality evidence. 3 ESGE recommends endoscopic papillectomy in patients with ampullary adenoma without intraductal extension, because of good results regarding outcome (technical and clinical success, morbidity, and recurrence). Strong recommendation, moderate quality evidence. 4 ESGE recommends en bloc resection of ampullary adenomas up to 20-30mm in diameter to achieve R0 resection, for optimizing the complete resection rate, providing optimal histopathology, and reduction of the recurrence rate after endoscopic papillectomy. Strong recommendation, low quality evidence. 5 ESGE suggests considering surgical treatment of ampullary adenomas when endoscopic resection is not feasible for technical reasons (e.g. diverticulum, size >4cm), and in the case of intraductal involvement (of >20mm). Surveillance thereafter is still mandatory. Weak recommendation, low quality evidence. 6 ESGE recommends direct snare resection without submucosal injection for endoscopic papillectomy. Strong recommendation, moderate quality evidence. 7 ESGE recommends prophylactic pancreatic duct stenting to reduce the risk of pancreatitis after endoscopic papillectomy. Strong recommendation, moderate quality evidence. 8 ESGE recommends long-term monitoring of patients after endoscopic papillectomy or surgical ampullectomy, based on duodenoscopy with biopsies of the scar and of any abnormal area, within the first 3 months, at 6 and 12 months, and thereafter yearly for at least 5 years. Strong recommendation, low quality evidence.
PrintDisplayed: 11/5/2024 18:18